Venture investment into U.S. biotechs is back at pre-COVID levels as of June of 2024. That should start to impact the biotools sector. Investment firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs. After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. Source: Biopharma Dive (More)